Publication

Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: the HERACLES clinical surveillance study

Authored by:

Picazo JJ, Ruiz-Contreras J, Casado-Flores J et al.

Full Citation:

Picazo JJ, Ruiz-Contreras J, Casado-Flores J et al. 2019. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: the HERACLES clinical surveillance study. Vaccine. 37(16).

View Publication

Additional key concepts from this publication:

The pneumococcal conjugate vaccine has been shown to significantly reduce the rate of antibiotic and multi-drug resistant strains of pneumococcal disease.

Key Evidence: Following the introduction of PCV7 and later PCV13 in Madrid, Spain, there was a 70% reduction in the incidence of invasive pneumococcal disease in children less than 15 years of age. There was also a pronounced decline in the percentages of penicillin- and cefotaxime-resistant strains of the pneumococcus bacteria. After PCV13 was introduced in 2010, cefotaxime resistance among meningitis patients completely disappeared and both cefotaxime and penicillin resistance among non-meningitis cases declined to very low levels (<3%).